Innova Captab is a two-engine Indian pharmaceutical company: a contract development and manufacturing (CDMO) business serving over 350 clients, and a branded generics (trade generics) operation with its own portfolio. In Q1 FY27, CDMO revenue was INR328.7 crores (up 32% year on year) and branded generics were INR142.2 crores (up 39%), giving consolidated revenue of INR470.9 crores, up 34%. Exports contributed 32% of revenue. The company runs multi-site facilities at Baddi, Dehradun, Taloja, and Jammu, with capabilities in cephalosporins, beta-lactams, penems, injectables, and oral solids and liquids. Full-year FY26 EBITDA margin was 15.4% (EBITDA INR250.3 crores), and Q1 FY27 came in at 16% (INR75.1 crores). Excluding Jammu, the base business runs at roughly 20% EBITDA margin, which suggests the overall margin is being dragged down by the newly commissioned facility. This is not a commodity business; it is a regulated manufacturing niche where repeat contracts and certifications matter more than price, though the Indian CDMO market is competitive and no player holds dominant share beyond five or six meaningful alternatives. The margin level today is average for manufacturing, but the trajectory points toward better than the 15-16% band as Jammu absorbs fixed costs.
The persistence of these economics rests on specific, hard-to-replicate barriers. Regulatory approvals are one: the Baddi cephalosporin block holds UK-MHRA approval, and all Jammu blocks received PIC/S certification via SMDC Ukraine, while facilities are EU-GMP compliant. Customer qualification cycles are another: the company reported that 14 of 15 existing Jammu clients had completed audits or were expected to start business during Q4 FY26 or Q1 FY27, meaning switching costs are high once a customer validates a plant. The CDMO model uses cost-plus pricing for raw materials, passing on API price swings to clients, which protects gross margin even when input costs are volatile. The branded generics side adds diversification with a 70% domestic, 30-35% export mix, and the Sharon acquisition brings regulated-market presence in Canada, UK, Europe, and Australia at better-than-average margins. These barriers are real but not unbreachable; API price volatility and timing lags in pass-through remain risk factors, yet the structural fit between customer need and company capability gives this business stickiness that pure contract manufacturers lack.
The inflection that makes this matter now is the Jammu facility ramp-up, which is the primary driver of operating leverage. In Q1 FY27, Jammu generated INR107 crores of revenue, up from INR90 crores in the prior quarter, corresponding to only 25-30% annualized capacity utilization. The facility has a stated peak revenue potential of INR1,400 crores at 65-70% utilization, meaning the revenue upside from here is substantial. Management has guided to 20% plus volume growth for FY27, with Jammu contributing significantly, and expects EBITDA growth to outpace revenue and PAT growth to outpace EBITDA as fixed depreciation and interest are already in the base. By 18-24 months from now, which is roughly the end of FY28 and early FY29, Jammu should be approaching 50-60% utilization if the current ramp trajectory holds, implying revenue of INR800-1,000 crores from that plant alone, versus the current annualized run rate of about INR428 crores. Additionally, the company has committed INR150-170 crores of capex across FY27 and FY28 for a new general oral block at Baddi, which has a revenue potential of INR450-500 crores at optimum capacity, with commercial production likely starting in FY28. Regulated-market approvals (UK-MHRA, PIC/S) will open export channels, and the semaglutide product in development is targeted for a wave-2 domestic launch, though timelines are not specified. The consolidated picture two years out is a business with 20% plus revenue growth, EBITDA margin expansion from the current 15-16% toward the 17-18% normalized level highlighted in the August 2026 call, and PAT growth that outpaces EBITDA due to the fixed cost base.
Management walk-talk shows a pattern of aggressive initial guidance, followed by realistic revisions and then delivery. On the February 2026 call, the FY26 Jammu revenue target was INR270-280 crores, revised down from the INR400 crores initially mentioned in August 2025, and the company hit that lower target. In the same call, management committed to 20%+ overall growth for FY27, and the Q1 FY27 result delivered 34% revenue growth, well above the guidance. The promise that Jammu would become EBITDA positive in the coming quarter (Q1 FY27) was kept, as the plant posted positive EBITDA of INR1-1.5 crores in that quarter. PAT breakeven at Jammu was originally expected by end of FY26, was then moved to FY27, and the latest guidance suggests it will happen during FY27. This mixed record indicates management is willing to trim expectations, but once trimmed, they meet the numbers. Capital allocation is disciplined: the Baddi expansion is planned at INR150-170 crores over two years, with interest capitalised, and maintenance capex of INR20-25 crores annually plus growth capex of INR20-30 crores. There is no indication of dilutive equity raises, and the balance sheet appears to support the spend from operating cash flow, which stood at INR182 crores for the first nine months of FY26 before working capital changes.
The earnings path is quantifiable. For FY27, revenue should be around INR1,950 crores (20% growth on FY26's ~INR1,630 crores), with EBITDA margin in the 15-16% band, implying EBITDA of INR292-312 crores. As Jammu utilization rises, EBITDA will grow faster than revenue, and with depreciation and interest largely fixed, PAT growth will be in the high 20s to 30% range. The kill shot is Jammu's ability to convert its 350+ CDMO customers into volume at the new facility, which depends on marquee audits, stability data, and product approvals from ROW countries expected by end of FY27. The single most important watchpoint is the pace of Jammu capacity utilization, since any delay in customer onboarding or regulatory approvals would push the operating leverage benefit out. Also monitor API price stability, as cost-plus pricing has a one-quarter timing lag that can compress margins. If Jammu scales as guided, the business in 18-24 months will be a higher-margin, more export-diversified CDMO player with an additional INR450-500 crores of revenue capacity from the Baddi block coming online, making the current margin and growth profile look conservative.
companyname: Innova Captab Limited ticker: INNOVACAP sector: Pharmaceuticals (CDMO & Branded Generics) Innova Captab is an integrated pharmaceutical company with two business lines that share the same manufacturing base: CDMO services (contract development and manufacturing for other pharma companies) and branded generics (its own products sold under its own brands). The CDMO business is the revenue engine; the branded generics business is the front-end growth engine. The company also holds API...
Read the full report →capex, margin expansion, regulatory approval, geographic expansion
FY27 revenue growth guided at 20%+ driven by Jammu plant utilization ramp-up and operational leverage
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Innova Captab Limited and 4,900+ companies.
5-day free pass. No card required.